ATE299140T1 - Farnesyl-protein transferase inhibitoren - Google Patents

Farnesyl-protein transferase inhibitoren

Info

Publication number
ATE299140T1
ATE299140T1 AT99965906T AT99965906T ATE299140T1 AT E299140 T1 ATE299140 T1 AT E299140T1 AT 99965906 T AT99965906 T AT 99965906T AT 99965906 T AT99965906 T AT 99965906T AT E299140 T1 ATE299140 T1 AT E299140T1
Authority
AT
Austria
Prior art keywords
protein transferase
transferase inhibitors
farnesyl protein
cells
disclosed
Prior art date
Application number
AT99965906T
Other languages
English (en)
Inventor
Alan B Cooper
Ronald J Doll
Johan A Ferreira
Ashit Ganguly
Viyyoor M Girijavallabhan
Arthur G Taveras
Jianping Chao
John J Baldwin
Chia-Yu Huang
Ge Li
Original Assignee
Schering Corp
Pharmacopeia Drug Discovery
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp, Pharmacopeia Drug Discovery filed Critical Schering Corp
Application granted granted Critical
Publication of ATE299140T1 publication Critical patent/ATE299140T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT99965906T 1998-12-23 1999-12-22 Farnesyl-protein transferase inhibitoren ATE299140T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22031498A 1998-12-23 1998-12-23
PCT/US1999/027958 WO2000039119A1 (en) 1998-12-23 1999-12-22 Novel inhibitors of farnesyl-protein transferase

Publications (1)

Publication Number Publication Date
ATE299140T1 true ATE299140T1 (de) 2005-07-15

Family

ID=22823058

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99965906T ATE299140T1 (de) 1998-12-23 1999-12-22 Farnesyl-protein transferase inhibitoren

Country Status (9)

Country Link
EP (1) EP1140909B1 (de)
JP (1) JP2002533455A (de)
CN (1) CN1181069C (de)
AT (1) ATE299140T1 (de)
AU (1) AU2158200A (de)
CA (1) CA2355744A1 (de)
DE (1) DE69926078T2 (de)
ES (1) ES2242444T3 (de)
WO (1) WO2000039119A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6432959B1 (en) * 1998-12-23 2002-08-13 Schering Corporation Inhibitors of farnesyl-protein transferase
US20020002171A1 (en) * 2000-01-28 2002-01-03 Chalquest Richard R. Materials and methods for killing nematodes and nematode eggs
CA2463626C (en) * 2001-10-17 2011-05-24 Schering Corporation Piperidine- and piperazineacetamines as 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
US7754722B2 (en) 2002-09-20 2010-07-13 Merck Serono Sa Piperazine derivatives and methods of use
WO2004071390A2 (en) * 2003-02-14 2004-08-26 Applied Research Systems Ars Holding N.V. Piperazine-2-carboxamide derivatives
DE102005017116A1 (de) * 2005-04-13 2006-10-26 Novartis Ag Hemmstoffe für Inhibitoren von Apoptose Proteinen (IAP)
US8017612B2 (en) 2006-04-18 2011-09-13 Japan Tobacco Inc. Piperazine compound and use thereof as a HCV polymerase inhibitor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5344830A (en) * 1992-12-10 1994-09-06 Merck & Co., Inc. N,N-diacylpiperazine tachykinin antagonists
WO1995000497A1 (en) * 1993-06-18 1995-01-05 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5880128A (en) * 1996-05-08 1999-03-09 Schering Corporation Carbonyl piperazinyl and piperidinyl compounds

Also Published As

Publication number Publication date
ES2242444T3 (es) 2005-11-01
DE69926078T2 (de) 2006-04-20
CN1346355A (zh) 2002-04-24
AU2158200A (en) 2000-07-31
DE69926078D1 (en) 2005-08-11
EP1140909A1 (de) 2001-10-10
CN1181069C (zh) 2004-12-22
WO2000039119A1 (en) 2000-07-06
EP1140909B1 (de) 2005-07-06
JP2002533455A (ja) 2002-10-08
CA2355744A1 (en) 2000-07-06

Similar Documents

Publication Publication Date Title
CA2293706A1 (en) N-substituted urea inhibitors of farnesyl-protein transferase
DE69628556D1 (de) Tricyclische verbindungen als inhibitoren von farnesyl protein transferase
ATE242231T1 (de) Carbonyl-piperaznyl und piperidinyl derivate zur hemmung farnesyl protein transferase
BR9908280A (pt) Inibidores de enzimas de fosfolipase
MY129998A (en) Saccharin derivative proteolytic enzyme inhibitors
FI961621A (fi) Proteiini:farnesyylitranseraasin substituoidut tetra- ja pentapeptidi-inhibiittorit
MY110104A (en) Saccharin derivative proteolytic enzyme inhibitors
PT871443E (pt) Inibicao dos intermediarios de produtos finais de glicosilacao avancada e pos-amadori
DE69622265D1 (de) Trizyklische verbindungen zur behandlung von zellproliferativen störungen
MY143570A (en) Compounds useful for inhibition of farnesyl protein transferase
TR199901274T2 (xx) Farnezil protein transferaz inhibit�rleri olarak yararl� yeni trisiklik piperidinil bile�ikleri
ATE299140T1 (de) Farnesyl-protein transferase inhibitoren
CA2266759A1 (en) 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase
CA2293358A1 (en) Tricyclic sulfonamide inhibitors of farnesyl-protein transferase
DE69722002D1 (de) Tricyclische n-cyanoimine als inhibitoren der farnesyl-protein transferase
ATE236149T1 (de) Tricyclische aminooxyamide derivate als farnesyl protein transferase inhibitoren
CA2293549A1 (en) Phenyl-substituted tricyclic inhibitors of farnesyl-protein transferase
ECSP982531A (es) Novedosos inhibidores de urea - n - sustituida de transferasa de proteina, farnesilo (case in0728)
CA2293713A1 (en) Bispyrido-cycloheptane compounds useful for inhibition of farnesyl protein transferase
ECSP982536A (es) Compuestos utiles para la inhibicion de transferasa de proteina al farnesilo ( case ino750k)

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties